{"preliminary_commentary":{"by_channel":{"bluesky_thread":4,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06107686","nct_id":"NCT06107686","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06107686. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic NSCLC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.","label":"Corhort A","type":"EXPERIMENTAL"},{"description":"YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic BC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.","label":"Corhort B","type":"EXPERIMENTAL"},{"description":"YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic HNSCC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.","label":"Corhort C","type":"EXPERIMENTAL"},{"description":"YL202 is provided as the lyophilized powder, 200 mg/vial. Other locally advanced cancer patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.","label":"Corhort D","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-11","type":"ESTIMATED"},"conditions":["NSCLC","Breast Cancer","HNSCC","Locally Advanced or Metastatic Solid Tumors"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"YL202 should be intravenously infused","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-26","lead_sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","official_title":"A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ORR assessed according to RECIST v1.1","timeFrame":"By the end of trial date, approximately within 36 months"},{"measure":"Determination of the recommended dose of YL202 in the pivotal clinical study","timeFrame":"By the end of trial date, approximately within 36 months"}],"references":[],"start_date":{"date":"2023-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06107686"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06107686"}